ARTICLE | Company News

Catalyst, Mosaic partner to develop anti-C3 proteases for dry AMD

November 30, 2017 11:37 PM UTC

Catalyst Biosciences Inc. (NASDAQ:CBIO) partnered with Mosaic Biosciences Inc. (Boulder, Colo.) to develop Catalyst’s preclinical anti-complement 3 (C3) proteases, including CB 2782, to treat dry age-related macular degeneration (AMD) and other inflammatory and retinal disorders. CB 2782 is derived from human membrane type serine protease 1 (MTSP-1) and cleaves C3.

The partners will seek to improve the pharmacokinetics of Catalyst’s candidates in order to generate products for once-quarterly intravitreal dosing with stronger potency than competitors. The partners will co-fund research. Catalyst is to retain global commercial rights, and Mosaic is eligible for sublicense fees and milestone payments, plus royalties...